{"title": "zugeh\u00f6rige Publikationen des strahlentherapeutischen Referenzzentrums f\u00fcr die Behandlung von hochmalignen B-Zell Lymphomen", "author": null, "url": "https://www.uniklinikum-saarland.de/de/einrichtungen/kliniken_institute/radiologie/strahlentherapie/referenzzentren/zugehoerige_publikationen_des_strahlentherapeutischen_referenzzentrums_fuer_die_behandlung_von_hochmalignen_b_zell_lymphomen", "hostname": "uniklinikum-saarland.de", "description": null, "sitename": "Universit\u00e4tsklinikum des Saarlandes", "date": "2013-10-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Publikationen\nHeld G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, R\u00fcbe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013 Nov 10;31(32):4115-22. doi: 10.1200/JCO.2012.48.0467. Epub 2013 Sep 23. PMID: 24062391\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/24062391/)\nMurawski N, Held G, Ziepert M, Kempf B, Viardot A, H\u00e4nel M, Witzens-Harig M, Mahlberg R, R\u00fcbe C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014 Jul 31;124(5):720-8. doi: 10.1182/blood-2013-10-535021. Epub 2014 Jun 17. PMID: 24939657.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/24939657/)\nPfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Tr\u00fcmper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. PMID: 18226581.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/18226581/)\nSchmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec;13(12):1250-9. doi: 10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16. PMID: 23168367.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/23168367/)\nHeld G, Murawski N, Ziepert M, Fleckenstein J, P\u00f6schel V, Zwick C, Bittenbring J, H\u00e4nel M, Wilhelm S, Schubert J, Schmitz N, L\u00f6ffler M, R\u00fcbe C, Pfreundschuh M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3. PMID: 24493716.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/24493716/)\nPfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, H\u00e4nel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, H\u00fcnerlit\u00fcrkoglu AN, Schmitz N, P\u00f6schel V, Rixecker T, Berdel C, R\u00fcbe C, Held G, Zwick C. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8. PMID: 28990173.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/28990173/)\nPoeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. PMID: 31868632.\n[Pubmed](https://pubmed.ncbi.nlm.nih.gov/31868632/)", "language": null, "image": null, "pagetype": null, "links": ["/de/", "/de/informationen/notfall", "/de/krankenversorgung/blutspende", "/de/aktuelles", "/de/einrichtungen/kliniken_institute", "/de/krankenversorgung", "/de/forschung", "/de/lehre", "/de/wir_ueber_uns/uks_leitbild", "/de/service", "/de/wir_ueber_uns/anschrift_und_anfahrt", "/de/", "/de/einrichtungen/kliniken_institute", "/de/einrichtungen/kliniken_institute", "/de/einrichtungen/kliniken_institute/radiologie", "/de/einrichtungen/kliniken_institute/radiologie/strahlentherapie", "/de/einrichtungen/kliniken_institute/radiologie/strahlentherapie/referenzzentren", "/de/einrichtungen/kliniken_institute/radiologie/strahlentherapie/referenzzentren", "https://pubmed.ncbi.nlm.nih.gov/24062391/", "https://pubmed.ncbi.nlm.nih.gov/24939657/", "https://pubmed.ncbi.nlm.nih.gov/18226581/", "https://pubmed.ncbi.nlm.nih.gov/23168367/", "https://pubmed.ncbi.nlm.nih.gov/24493716/", "https://pubmed.ncbi.nlm.nih.gov/28990173/", "https://pubmed.ncbi.nlm.nih.gov/31868632/", "http://24pluskliniken.de/", "http://www.uni-saarland.de", "/de/informationen/a_z", "/de/impressum", "/de/datenschutz", "http://www.aktionsbuendnis-patientensicherheit.de", "http://www.uniklinika.de/"]}